Eculizumab for dense deposit disease and C3 glomerulonephritis - Wikidata - awgldk - TriplyDB

Eculizumab for dense deposit disease and C3 glomerulonephritis

Eculizumab for dense deposit disease and C3 glomerulonephritis

http://www.wikidata.org/entity/Q24632330

about

Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN Overview of C3 Glomerulopathy Monoclonal antibody therapy and renal transplantation: focus on adverse effects Complement cascade and kidney transplantation: The rediscovery of an ancient enemy Atypical haemolytic uraemic syndrome with underlying glomerulopathies. A case series and a review of the literature Update on membranoproliferative GN C5 inhibition prevents renal failure in a mouse model of lethal C3 glomerulopathy.Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies.The use of eculizumab in renal transplantation.Novel use of intravenous immunoglobulin G in complement factor H missense mutation: a case report.Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.Moss-Produced, Glycosylation-Optimized Human Factor H for Therapeutic Application in Complement Disorders.Defining the complement biomarker profile of C3 glomerulopathy Defective complement inhibitory function predisposes to renal disease.Successful management of a patient with a C3 Glomerulonephritis and crescentic pattern: a case report Current concepts in C3 glomerulopathy.Clinico-pathologic spectrum of C3 glomerulopathy-an Indian experience.Complement involvement in kidney diseases: From physiopathology to therapeutical targeting Eculizumab and recurrent C3 glomerulonephritis Treatment options for C3 glomerulopathy Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation?Compstatin analog Cp40 inhibits complement dysregulation in vitro in C3 glomerulopathy Timing of eculizumab therapy for C3 glomerulonephritis.Eculizumab in Pediatric Dense Deposit Disease.Complement Dysregulation and Disease: Insights from Contemporary Genetics.Applying complement therapeutics to rare diseases.Kidney diseases caused by complement dysregulation: acquired, inherited, and still more to come.Primary glomerulonephritis: A review of important recent discoveries.New classification of membranoproliferative glomerulonephritis: a good start but a long way to go.C3 glomerulopathy-associated CFHR1 mutation alters FHR oligomerization and complement regulation.Complement receptor 3 mediates renal protection in experimental C3 glomerulopathy.Cutting edge: the NLRP3 inflammasome links complement-mediated inflammation and IL-1β release.Immune and inflammatory role in renal disease.Dense deposit disease and C3 glomerulopathy C3 glomerulopathy: consensus report.C3 glomerulopathy: clinicopathologic features and predictors of outcome.The complement cascade and renal disease.Complement related kidney diseases: Recurrence after transplantation.American Society of Nephrology clinical pathological conference.Pathogenesis of the C3 glomerulopathies and reclassification of MPGN.

P2860

Q26741542-C4EA6466-FC01-43F5-AA81-174E93CB5CA5 Q26747262-A8F5654C-EE76-40FA-9D9F-14FFDB4BAC46 Q26826880-55B6AC1A-A1DA-472B-967A-56852346ABEC Q26829790-598890D8-583E-4494-9419-5D74C26B40AD Q26864297-99D49072-1BBF-4196-9D76-74E3560F9E11 Q26866127-2D3C2A5F-0B6D-41E1-84D8-4BF03A51561E Q30274884-FC8445A0-5AD7-4673-9F78-900C9B1D39F6 Q33403607-C6AAD9EB-44F1-4832-A0DC-C445A91518FB Q33406570-6D45C6DB-9D96-44BD-8EF2-4246F9765BEE Q33410111-4E1E610C-D57E-4699-B832-931A9D43A8CC Q33436307-3F84BF43-FC47-48E0-A455-74BE9E5EF443 Q33437488-707E7A4F-3B9C-4293-8902-90F767B5C1F0 Q34455125-F4492415-806D-4135-8C4F-1D159424875B Q34465747-2A6FABE4-2448-48E0-A588-B2BA4AE4A19E Q34514835-6D73E3CC-17F5-49F5-8DE5-802E9C3116D1 Q34574482-0E19A142-1293-4682-AE9E-C29928609915 Q35246525-081B9216-913A-414C-9D4F-1966289A5857 Q35567841-992D0D90-11D0-4E55-BDEA-CBA549F00E72 Q35597310-2DA04D0C-8DBC-4DE3-81FE-D7D0E772710D Q35624672-DCE15909-3910-4D24-8180-441B5ACB93FF Q35750545-30B5C48A-4B01-42DF-BAC8-C556376CE658 Q35877192-84605182-0BDA-4A3E-8654-1AF520A959ED Q35891599-90A0AE11-5064-4CA7-A9FC-C1C98B882BD1 Q36123605-18528F4E-8194-44A3-8A00-B8630DE5E034 Q36221928-036D265D-CFB2-4CA7-A282-36D0E21F3ABB Q36315497-1C7F3DCA-8CB0-476F-9193-A30C10660E7D Q36438860-0578E4D3-D16A-46D1-944F-3203F9FC9785 Q36465902-256DCE7E-4BE6-4E0E-9121-23A898DE97E1 Q36466296-BC19FB07-6109-4EC0-A231-232192AB6932 Q36891110-8F53E2F5-CC5D-45CA-A78C-47748EA361DE Q36907945-53DC02A7-945C-40B6-B360-8C786B948325 Q37031990-6716D3D2-888A-4667-91D9-C448A79BB02C Q37243199-94B0F1C2-9BE8-4C8F-A841-4DAD35BF0EE9 Q37286653-CEC2321C-25D2-48BD-8961-94EA475C4F51 Q37348685-0148DC55-02AB-41BA-B746-264EAE7DDE31 Q37426966-43D4ECC5-08D4-4939-AF0A-0988B0C7B83D Q37502706-59523ACC-F55B-43CB-87FD-A017F43903F0 Q37522557-CA95DA90-D668-43FF-B9FA-ECD22C3E2851 Q37682273-59747248-558C-4E05-BAE4-FA0280F4B9CE Q38048606-F79AB9A9-20B8-49EB-A094-DC9E696DCB1A

P2860

Eculizumab for dense deposit disease and C3 glomerulonephritis

http://www.wikidata.org/entity/Q24632330

description

2012 nî lūn-bûn

@nan

2012 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Eculizumab for dense deposit disease and C3 glomerulonephritis

@ast

Eculizumab for dense deposit disease and C3 glomerulonephritis

@en

Eculizumab for dense deposit disease and C3 glomerulonephritis

@nl

type

label

Eculizumab for dense deposit disease and C3 glomerulonephritis

@ast

Eculizumab for dense deposit disease and C3 glomerulonephritis

@en

Eculizumab for dense deposit disease and C3 glomerulonephritis

@nl

prefLabel

Eculizumab for dense deposit disease and C3 glomerulonephritis

@ast

Eculizumab for dense deposit disease and C3 glomerulonephritis

@en

Eculizumab for dense deposit disease and C3 glomerulonephritis

@nl

P1433

Q24632330-FD8AF2EA-BFFD-4090-8C2C-4431D0607544

P1476

Q24632330-ECD0E9D3-8D8E-468D-B86C-B9585C44778C

P2093

Q24632330-125A304C-B52A-49AB-83D4-98F16BE51B4E

Q24632330-277ABBF3-37C9-4F88-95FE-4618C021E1F2

Q24632330-367D8D75-305E-4175-A04C-F2099D69E862

Q24632330-36B3387E-6658-4F1C-95F8-6BCD42834DD8

Q24632330-3D2B3682-EAB6-4112-AB9F-B06F0AFC3CE8

Q24632330-4B29AEF8-D987-4F70-94A6-AAF7C9076648

Q24632330-8620C880-0103-4443-B811-B96D4C570515

Q24632330-A13B967B-69B7-4E55-97E4-50DA9EA38C23

Q24632330-B5E5EC6D-73E4-456A-A160-9F4AC9AE32BC

Q24632330-D7DCC410-E97B-4D03-98A1-6466FABA39A7

P2860

Q24632330-175E0A24-8BE1-40A6-8786-E985C5E778E8

Q24632330-32798EA9-A4C1-4B4A-A0A3-38BBBFEFCFAD

Q24632330-4287CF9C-C5C9-40F4-96FE-8E313D0F60DB

Q24632330-43F14FB4-D02A-44BE-B044-0B5E4D1FE1E5

Q24632330-61267008-5009-4BC8-8CA1-02E085351AFA

Q24632330-715D2272-30A0-4189-85B7-1EEFBC51E7EF

Q24632330-7C355418-EBDF-4DDE-8E90-2DFF91AEEF5D

Q24632330-81AFE962-0D5E-4A36-962E-E65588C3A149

Q24632330-82807856-6A22-4E30-94F3-E9D47A56B508

Q24632330-B4113CB1-6562-4C3F-BC3B-7D74038CC7AC

P304

Q24632330-E5697A8B-F56F-412E-A531-F8270CAFD980

P31

Q24632330-3D689655-69AA-43B7-A4AD-D999EF5AB2A6

P3181

Q24632330-C91839CC-A4B2-44B2-A5F9-DE45FEED8390

P356

Q24632330-2379CFA3-A2E3-4EDB-BB75-FA6EE7A09DAD

P407

Q24632330-9731EC60-28BA-4E38-95D7-1EA18E5768B5

P433

Q24632330-82D462F8-8F4C-462D-938A-A6341024B9B7

P478

Q24632330-AF501C1D-E4BF-4B1C-8294-C5D12D408AA8

P577

Q24632330-BFEB5BF4-51FB-4795-B81E-5CF091E4087B

P698

Q24632330-B176B935-9A1C-4EC2-B5DC-D96E27EB00BE

P921

Q24632330-3515E03E-F4D8-41BE-8681-11DA9B2828FB

P932

Q24632330-404736AA-232B-44E3-9BE3-39FD4EB1D645

P3181

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Eculizumab for dense deposit disease and C3 glomerulonephritis

@en

P2093

Andrew S Bomback

http://www.w3.org/2001/XMLSchema#string

Eliot C Heher

http://www.w3.org/2001/XMLSchema#string

Gaetano R Barile

http://www.w3.org/2001/XMLSchema#string

Gerald B Appel

http://www.w3.org/2001/XMLSchema#string

Glen S Markowitz

http://www.w3.org/2001/XMLSchema#string

Jai Radhakrishnan

http://www.w3.org/2001/XMLSchema#string

Leal Herlitz

http://www.w3.org/2001/XMLSchema#string

M Barry Stokes

http://www.w3.org/2001/XMLSchema#string

Pietro A Canetta

http://www.w3.org/2001/XMLSchema#string

Richard J Smith

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis

Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome

Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease)

Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion

Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome

Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

Dense deposit disease: clinicopathologic study of 32 pediatric and adult patients

New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab.

Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement

Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation.

P304

748-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1798900

http://www.w3.org/2001/XMLSchema#string

P356

10.2215/CJN.12901211

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22403278

http://www.w3.org/2001/XMLSchema#string

P921

glomerulonephritis

P932

3338285

http://www.w3.org/2001/XMLSchema#string